Loading...
Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
The dysregulation of NLRP3 inflammasome can cause uncontrolled inflammation and drive the development of a wide variety of human diseases, but the medications targeting NLRP3 inflammasome are not available in clinic. Here, we show that tranilast (TR), an old anti‐allergic clinical drug, is a direct...
Saved in:
| Published in: | EMBO Mol Med |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley and Sons Inc.
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5887903/ https://ncbi.nlm.nih.gov/pubmed/29531021 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201708689 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|